MedTrace Logo

Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis.

NCT04190108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 259

Last updated 2019-12-11

No results posted yet for this study

Summary

Background.Recent epidemiologic studies have shown an association between psoriasis, psoriatic arthritis (PsA) and inflammatory bowel diseases (IBD). Recently, measurement of fecal calprotectin (FC) demonstrated a good sensitivity and specificity for intestinal inflammation.

Primary objective of present study was to evaluate the presence of occult bowel inflammation in patients with PsA as expressed by elevated levels of FC. Secondary objectives were to investigate the correlation between the levels FC and clinical and laboratory features, and the outcome of CF-positive patients in terms of IBD development.

Conditions

Interventions

DIAGNOSTIC_TEST

Fecal calprotectin assay

FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.

Sponsors & Collaborators

  • Giulia Franchi,Department of Rheumatology, Hospital of Prato

    collaborator UNKNOWN

  • Maurizio Benucci,S.Giovanni di Dio Hospital

    collaborator UNKNOWN

  • Raffaele Scarpa, Rheumatology Unit, University of Naples Federico II, Naples

    collaborator UNKNOWN

  • Francesco Caso, Rheumatology Unit, University of Naples Federico II, Naples

    collaborator UNKNOWN

  • Rosario Foti,Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania

    collaborator UNKNOWN

  • Antonio Carletto,Rheumatology Unit, AOUI, Verona.

    collaborator UNKNOWN

  • Elisa Visalli,Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania

    collaborator UNKNOWN

  • Laura Niccoli,Department of Rheumatology, Hospital of Prato

    collaborator UNKNOWN

  • Hospital of Prato

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-02
Primary Completion
2018-12-31
Completion
2019-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04190108 on ClinicalTrials.gov